EQL Pharma AB (publ) reported earnings results for the third quarter and nine months ended December 31, 2022. For the third quarter, the company reported sales was SEK 80.19 million compared to SEK 117.61 million a year ago. Net income was SEK 11.95 million compared to SEK 17.2 million a year ago. Basic earnings per share from continuing operations was SEK 0.41 compared to SEK 0.59 a year ago.
For the nine months, sales was SEK 199.58 million compared to SEK 206.73 million a year ago. Net income was SEK 26.8 million compared to SEK 25.04 million a year ago. Basic earnings per share from continuing operations was SEK 0.92 compared to SEK 0.86 a year ago.